TrueVue an innovative monitoring system to improve patient outcomes, reduce mortality and reduce healthcare costs

Deltex Medical因开发TrueVue而荣获英国创新奖，TrueVue是一项颠覆性技术，用于诊断和管理外科和危重护理患者的血流动力学。它专为所有医院的所有患者设计，从新生儿到成人，无论是麻醉的还是清醒的。随着人口老龄化，今天的医学面临着越来越复杂的病例。通过改进监测来保护患者免受血流动力学错误的影响，将拯救数千人的生命，改善结果并降低成本。诊断血流动力学设备需要显示血流和压力的相互作用才能真正有效。血流动力学不稳定和低血压经常发生，会导致心肌梗死、中风和肾脏损伤等后果。并发症具有严重的临床和经济后果；意外的重症监护入院；更长的住院时间；更多的再次住院；增加30天的死亡率；出院后患者寿命缩短。仅靠测量血压的监管者无法满足所有医院设置的所有患者的这一需求。新的TrueVue速度压力环系统是第一个在整个心跳过程中同时显示主动脉血流和主动脉血压的监测器。TrueVue将为外科和重症护理患者的患者安全做出重大贡献。TrueVue将使用多普勒超声和其他非侵入性方法测量血流速度，并将其与标准的动脉血压测量相结合。该系统目前可以用于所有主要的外科手术和重症监护病房；Deltex已经预见到非侵入性方法的发展，可以应用于所有手术和术后护理程序。英国在血液动力学和增强恢复计划方面处于全球临床领先地位。TrueVue基于健全的血流动力学实践，对英国来说既是患者安全的重大进步，也是全球商机。TrueVue将满足仅在英国就有近60万外科患者、9万名重症监护患者入院的市场需求，以及一个拥有近4000万重大/高风险手术和ICU的全球市场。随着通过非侵入性方法扩展到所有类别的手术，该技术每年拥有2.78亿例手术的潜在市场。Deltex Medical预计其市场份额将增加5倍，在前6年的销售收入达到3500万GB。

Deltex Medical has been awarded an Innovate UK Smart Award to develop TrueVue - a disruptive technology for the diagnosis and management of the haemodynamics of surgical and critical care patients. It is designed for all patients from new-born to adult, anaesthetised or awake, across all hospital settings. Medicine today faces increasingly complex cases as the population ages. Protecting patients from haemodynamic errors through improved monitoring would save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of blood flow and pressure if it is to be truly effective.Haemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer hospital stay; increased readmissions; increased 30-day mortality; and shorter patient lifespan after discharge.Monitors dependent on blood pressure measurement alone are failing to meet this need for all patients across all hospital settings. The novel TrueVue Velocity Pressure Loops system is the first monitor to display both aortic blood flow and aortic blood pressure simultaneously throughout the heartbeat. TrueVue will be a significant contribution to patient safety for surgical and critical care patients.TrueVue will operate by use of Doppler ultrasound and other non-invasive methods to measure blood flow velocity and combine this with standard measures of arterial blood pressure. The system can currently be used in all major surgical procedures and intensive care units; and with developments in non-invasive methods already foreseen by Deltex, could be applied across all surgical and after care procedures.The UK is a global clinical leader in haemodynamics and Enhanced Recovery Programmes. TrueVue is based on sound haemodynamic practices and is both a significant patient safety advance and a global business opportunity for the UK. TrueVue will address a market need in the UK alone of nearly 600,000 surgical patients, 90,000 intensive care admissions and a global market of nearly 40million in major/high-risk surgery and ICU. With expansion into all categories of surgery through non-invasive methods the technology has a potential market of 278million procedures annually.Deltex Medical expects to increase its market share, and revenues 5-fold to £35m in the first 6 years of sales.